OXURION NV (OXUR.BR) Stock Price, Forecast & Analysis
Europe - Euronext Brussels - EBR:OXUR - BE0974487192 - Common Stock
OXUR.BR Key Statistics, Chart & Performance
The current stock price of OXUR.BR is 0.0072 EUR. In the past month the price decreased by -29.41%. In the past year, price decreased by -97%.
OXUR.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 67.75 | 44.13B | ||
| 1AE.DE | ARGENX SE | 67.67 | 44.08B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.56B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.39B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.37B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.85B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.85B | ||
| NANO.PA | NANOBIOTIX | N/A | 940.20M | ||
| 5CV.DE | CUREVAC NV | 6.24 | 815.12M | ||
| IVA.PA | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20.44 | 681.29M | ||
| FYB.DE | FORMYCON AG | N/A | 452.35M |
Related stock screener links
About OXUR.BR
Company Profile
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Leuven (Louvain), Vlaams-Brabant and currently employs 11 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
Company Info
OXURION NV
Gaston Geenslaan 1
LEUVEN (LOUVAIN) VLAAMS-BRABANT BE
Employees: 11
Phone: 3216751310
OXURION NV / OXUR.BR FAQ
What does OXURION NV do?
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Leuven (Louvain), Vlaams-Brabant and currently employs 11 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
What is the current price of OXUR stock?
The current stock price of OXUR.BR is 0.0072 EUR. The price decreased by -2.7% in the last trading session.
What is the dividend status of OXURION NV?
OXUR.BR does not pay a dividend.
What is the ChartMill technical and fundamental rating of OXUR stock?
OXUR.BR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is OXURION NV (OXUR.BR) stock traded?
OXUR.BR stock is listed on the Euronext Brussels exchange.
What is the employee count for OXUR stock?
OXURION NV (OXUR.BR) currently has 11 employees.
What is the ownership structure of OXURION NV (OXUR.BR)?
You can find the ownership structure of OXURION NV (OXUR.BR) on the Ownership tab.
OXUR.BR Technical Analysis
OXUR.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OXUR.BR. Both the profitability and financial health of OXUR.BR have multiple concerns.
OXUR.BR Financial Highlights
Over the last trailing twelve months OXUR.BR reported a non-GAAP Earnings per Share(EPS) of 0.61. The EPS increased by 101.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 97950% | ||
| ROA | 39.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |